FDA label
What is Rytary used for?
Rytary contains levodopa and carbidopa hydrate. The FDA-approved uses below are quoted from the Indications and Usage section of its DailyMed label.
Source: DailyMed SPL label file dated 2026-10-23. Publisher page
The FDA label says: “RYTARY is indicated for the treatment of Parkinson's disease, post-encephalitic parkinsonism, and parkinsonism that may follow carbon monoxide intoxication or manganese intoxication.”
Run it in Rivvi
Which 2027 plans near you dropped or restricted Rytary?
Tier changes and new prior auth, step therapy or quantity limits, plan by plan.
Free to start. Opens Rivvi, the AI workspace for healthcare teams.
Rytary, capsule, extended release
Indications and Usage, quoted from the label by Amneal Pharmaceuticals LLC (NDA203312). Cross-references to other label sections are left out.
RYTARY is indicated for the treatment of Parkinson's disease, post-encephalitic parkinsonism, and parkinsonism that may follow carbon monoxide intoxication or manganese intoxication.
Source: DailyMed label, set id 6c1f7cd4-de56-45c1-a734-5e77b4aeb6f7, version 26, effective March 26, 2026. NDC 64896-661, one of 4 listings for this product.
Questions
What is Rytary used for?
The FDA label says: “RYTARY is indicated for the treatment of Parkinson's disease, post-encephalitic parkinsonism, and parkinsonism that may follow carbon monoxide intoxication or manganese intoxication.”
What drug class is Rytary?
FDA lists levodopa and carbidopa hydrate in the Aromatic Amino Acid established pharmacologic class.
Does this page cover off-label uses or dosing?
No. This page shows only the Indications and Usage section of the FDA label. Ask a pharmacist or prescriber about dosing.